- Conditions
- Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma, Metastatic Genitourinary System Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 17
- States / cities
- Encinitas, California • Irvine, California • La Jolla, California + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,088
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Bladder Urothelial Carcinoma
- Interventions
- Stereotactic body radiotherapy, Cemiplimab, Cemiplimab and Fianlimab, Radical cystectomy
- Radiation · Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Non-muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- UroAmp Test (Convergent Genomics, Inc.)
- Diagnostic Test
- Lead sponsor
- Lahey Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Burlington, Massachusetts
- Conditions
- Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma
- Interventions
- SEphB4-HSA, Pembrolizumab, Gemcitabine, Cisplatin, Enfortumab vedotin
- Drug
- Lead sponsor
- Vasgene Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma), Endometrial Cancer, Hypertension, Hyperlipidemia (E.G., Hypercholesterolemia), Diabetes Mellitus
- Interventions
- PC2: Primary Care Connect
- Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Prostate Cancer, Pancreatic Cancer, Bladder Cancer
- Interventions
- [124I] PSCA-Minibody PET/CT imaging of the whole body
- Radiation
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Urothelial Carcinoma Bladder
- Interventions
- Sasanlimab, Stereotactic Body Radiation Therapy, Radical Cystectomy + pelvic lymph node dissection + urinary diversion
- Drug · Radiation · Procedure
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Transitional Cell Carcinoma, Bladder Cancer
- Interventions
- Docetaxel, vandetanib, Placebo
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Interventions
- UGN-102
- Drug
- Lead sponsor
- UroGen Pharma Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- Homewood, Alabama • Indianapolis, Indiana • Greensboro, North Carolina + 2 more
- Conditions
- Bladder Cancer
- Interventions
- Everolimus and Intravesical Gemcitabine
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bladder Cancer
- Interventions
- Collect Blood and Survey Instruments
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Nonmuscle-invasive Bladder Cancer
- Interventions
- T3011
- Biological
- Lead sponsor
- ImmVira Pharma Co. Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 9
- States / cities
- Queen Creek, Arizona • Los Angeles, California • Orlando, Florida + 6 more
- Conditions
- Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer, Renal Cancer, Head/Neck Cancers
- Interventions
- Stereotactic Body Radiotherapy, Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab
- Radiation · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 10
- States / cities
- Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
- Conditions
- Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma, Endometrial Carcinoma, Malignant Uterine Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Malignant Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Solid Neoplasm, Stage III Bladder Cancer, Stage III Prostate Cancer, Stage III Renal Cell Cancer, Stage IIIA Breast Cancer, Stage IIIA Cervical Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Breast Cancer, Stage IIIB Cervical Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Breast Cancer, Stage IIIC Ovarian Cancer, Stage IV Breast Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Renal Cell Cancer, Stage IVA Bladder Cancer, Stage IVA Cervical Cancer, Stage IVB Bladder Cancer, Stage IVB Cervical Cancer
- Interventions
- Laboratory Biomarker Analysis, Nanoparticle Albumin-Bound Rapamycin, Quality-of-Life Assessment
- Other · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Pembrolizumab, Photon Beam Radiation Therapy, Positron Emission Tomography, Questionnaire Administration, Transurethral Resection of Bladder Tumor
- Procedure · Biological · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 165
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 130 more
- Conditions
- Bladder Cancer
- Interventions
- Extracorporeal Urinary Diversion, Intracorporal Urinary Diversion
- Procedure
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Urothelial Carcinoma
- Interventions
- KHK2455, Avelumab
- Drug
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- St. Petersburg, Florida • Iowa City, Iowa • Santa Fe, New Mexico + 2 more
- Conditions
- Bladder Cancer, Metastatic Bladder Cancer, Invasive Bladder Cancer
- Interventions
- Avelumab
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Houston, Texas
- Conditions
- Bladder Cancer
- Interventions
- SUTENT, Placebo
- Drug · Other
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Chicago, Illinois • Ann Arbor, Michigan + 5 more
- Conditions
- Hematuria - Cause Not Known
- Interventions
- Cxbladder Triage Plus
- Diagnostic Test
- Lead sponsor
- Pacific Edge Limited
- Industry
- Eligibility
- 18 Years to 88 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 20
- States / cities
- Homewood, Alabama • Mobile, Alabama • Fresno, California + 15 more
- Conditions
- Non-muscle Invasive Bladder Cancer
- Interventions
- eRapa, Placebos
- Drug
- Lead sponsor
- Robert Svatek
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Dallas, Texas • San Antonio, Texas
- Conditions
- Cancer
- Interventions
- Fentanyl sublingual spray, Placebo
- Drug
- Lead sponsor
- INSYS Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Chandler, Arizona
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Interventions
- carboplatin, cisplatin, doxorubicin hydrochloride, methotrexate, paclitaxel, vinblastine
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more
- Conditions
- Bladder Cancer
- Interventions
- Nivolumab, Questionnaires
- Drug · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas